Buspirone augmentation of a selective serotonin reuptake inhibitor: efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence.
Sprenger
D
D
D015057:1-Naphthylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D000437:Alcoholism / Q000523:psychology / Q000534:rehabilitation*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001008:Anxiety Disorders / Q000523:psychology / Q000534:rehabilitation*; D002065:Buspirone / Q000008:administration & dosage* / Q000009:adverse effects; D015897:Comorbidity; D003866:Depressive Disorder / Q000523:psychology / Q000534:rehabilitation*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D020280:Sertraline; D016896:Treatment Outcome
D015057:1-Naphthylamine; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D002065:Buspirone; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline